[go: up one dir, main page]

PE20060722A1 - Compuestos heterociclicos como antagonistas del receptor cgrp - Google Patents

Compuestos heterociclicos como antagonistas del receptor cgrp

Info

Publication number
PE20060722A1
PE20060722A1 PE2005001288A PE2005001288A PE20060722A1 PE 20060722 A1 PE20060722 A1 PE 20060722A1 PE 2005001288 A PE2005001288 A PE 2005001288A PE 2005001288 A PE2005001288 A PE 2005001288A PE 20060722 A1 PE20060722 A1 PE 20060722A1
Authority
PE
Peru
Prior art keywords
oxo
piperidin
alkyl
antagonists
cyclohepta
Prior art date
Application number
PE2005001288A
Other languages
English (en)
Inventor
Prasad V Chaturvedula
Stephen E Mercer
Haiquan Fang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060722A1 publication Critical patent/PE20060722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R2 ES H, HALO, HIDROXI, ENTRE OTROS; R3 ES H, HIDROXI, HALO, ENTRE OTROS; R4 ES H, HALO, ALQUILO(C1-C6), ENTRE OTROS, R5 ES H, ALQUILO(C1-C6); R6 ES H, ALQUILO(C1-C6), ENTRE OTROS; X-Y ES AMINOCARBONILO, OXICARBONILO, METILENCARBONILO, ENTRE OTROS; n ES 0 Y 1. SON COMPUESTOS PREFERIDOS: (9-BENCIL-8-OXO-3,6,7,8,9,10-HEXAHIDRO-2,3,9-TRIAZA-(R)-CICLOHEPTA[e]INDEN-7-IL)-AMIDA DEL ACIDO 4-(2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-PIPERIDIN-1-CARBOXILICO, (9-METIL-8-OXO-3,6,7,8,9,10-HEXAHIDRO-2,3,9-TRIAZA-(R)-CICLOHEPTA[e]INDEN-7-IL)-AMIDA DEL ACIDO 4-(2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-PIPERIDIN-1-CARBOXILICO, [8-OXO-9-(2-PIPERIDIN-1-IL-ETIL)-3,6,7,8,9,10-HEXAHIDRO-2,3,9-TRIAZA-(R)-CICLOHEPTA[e]INDEN-7-IL]-AMIDA DE 4-(2-OXO-1,4-DIHIDRO-2H-QUINAZOLIN-3-IL)-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DEL PEPTIDO RELACIONADO CON EL GEN DE CALCITONINA (CGRP), PUDIENDO SER UTILES EN ENFERMEDADES TALES COMO INFLAMACION NEUROGENICA, MIGRANA
PE2005001288A 2004-11-03 2005-11-03 Compuestos heterociclicos como antagonistas del receptor cgrp PE20060722A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62465504P 2004-11-03 2004-11-03
US67809905P 2005-05-05 2005-05-05
US11/247,697 US7384930B2 (en) 2004-11-03 2005-10-11 Constrained compounds as CGRP-receptor antagonists

Publications (1)

Publication Number Publication Date
PE20060722A1 true PE20060722A1 (es) 2006-08-16

Family

ID=36262864

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001288A PE20060722A1 (es) 2004-11-03 2005-11-03 Compuestos heterociclicos como antagonistas del receptor cgrp

Country Status (14)

Country Link
US (2) US7384930B2 (es)
EP (1) EP1809633A1 (es)
JP (1) JP2008519074A (es)
KR (1) KR20070085647A (es)
AR (1) AR051755A1 (es)
AU (1) AU2005305245A1 (es)
BR (1) BRPI0517965A (es)
CA (1) CA2586370A1 (es)
IL (1) IL182828A0 (es)
MX (1) MX2007005119A (es)
NO (1) NO20072188L (es)
PE (1) PE20060722A1 (es)
TW (1) TW200628470A (es)
WO (1) WO2006052378A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
PT1539766T (pt) * 2002-06-05 2017-03-02 Bristol Myers Squibb Co Antagonistas de recetor de péptido relacionado com o gene de calcitonina
TW200524601A (en) * 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7879591B2 (en) * 2004-11-04 2011-02-01 E.I. Du Pont De Nemours And Company High eicosapentaenoic acid producing strains of Yarrowia lipolytica
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB0515323D0 (en) 2005-07-26 2005-08-31 Electrophoretics Ltd Mass labels
US7834007B2 (en) * 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
CN101309704B (zh) 2005-11-14 2012-10-10 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
WO2007061692A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam tricyclic cgrp receptor antagonists
US7968540B2 (en) 2005-11-18 2011-06-28 Merck Sharp & Dohme Corp. Spirohydantoin tricyclic CGRP receptor antagonists
WO2007061676A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
US7851464B2 (en) * 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
ATE517903T1 (de) * 2006-05-02 2011-08-15 Bristol Myers Squibb Co Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP2049532B1 (en) * 2006-07-21 2010-06-02 Vertex Pharmaceuticals, Inc. Cgrp receptor antagonists
WO2008070014A2 (en) * 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2008073251A1 (en) * 2006-12-08 2008-06-19 Merck & Co., Inc. Constrained spirocyclic compounds as cgrp receptor antagonists
CA2672230A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists
WO2009105348A1 (en) * 2008-02-19 2009-08-27 Merck & Co., Inc. Imidazobenzazepine cgrp receptor antagonists
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
WO2012129014A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
BR112013026744B1 (pt) 2011-04-21 2022-05-17 Origenis Gmbh Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
PL3052096T3 (pl) 2013-10-03 2018-07-31 Kura Oncology Inc Inhibitory ERK i sposoby ich zastosowania
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10287337B2 (en) * 2015-06-01 2019-05-14 Afasci, Inc. Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
US20230026611A1 (en) * 2019-10-07 2023-01-26 D. E. Shaw Research, Llc ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
CN118666833B (zh) * 2024-05-30 2024-12-13 龙曦宁（上海）医药科技有限公司 一种2-（5-溴吡啶-3-基）奎宁环的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009046A1 (en) 1995-09-05 1997-03-13 Smithkline Beecham Corporation Compounds and methods
AU4261697A (en) 1996-09-09 1998-03-26 Smithkline Beecham Corporation Compounds and methods
ATE266673T1 (de) 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2327695A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU6211499A (en) 1998-09-30 2000-04-17 Merck & Co., Inc. Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19963868A1 (de) 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2004518613A (ja) 2000-08-01 2004-06-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
US7193070B2 (en) 2001-09-27 2007-03-20 Merck & Co., Inc. Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
DE10206770A1 (de) 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
PT1539766T (pt) 2002-06-05 2017-03-02 Bristol Myers Squibb Co Antagonistas de recetor de péptido relacionado com o gene de calcitonina
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20040076587A1 (en) 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
EP1534681A1 (en) 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2004082678A1 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Aryl spirohydantoin cgrp receptor antagonists
ATE394400T1 (de) 2003-03-14 2008-05-15 Merck & Co Inc Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
JP4673295B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
AU2004226018B2 (en) 2003-03-14 2009-08-27 Merck Sharp & Dohme Corp. Benzodiazepine spirohydantoin CGRP receptor antagonists
ATE535514T1 (de) 2003-03-14 2011-12-15 Merck Sharp & Dohme Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
US20040248816A1 (en) 2003-04-01 2004-12-09 Boehringer Ingelheim International Gmbh Treatment of migraine
ATE466860T1 (de) 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1812982B (zh) 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
US20050032783A1 (en) 2003-07-07 2005-02-10 Boehringer Ingelheim International Gmbh Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
WO2005072308A2 (en) 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018796A1 (de) 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2007533685A (ja) 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたｃｇｒｐアンタゴニストの使用
US20050233980A1 (en) 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
CA2672230A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists

Also Published As

Publication number Publication date
AU2005305245A1 (en) 2006-05-18
KR20070085647A (ko) 2007-08-27
IL182828A0 (en) 2007-08-19
CA2586370A1 (en) 2006-05-18
US7384930B2 (en) 2008-06-10
BRPI0517965A (pt) 2008-10-28
NO20072188L (no) 2007-07-19
EP1809633A1 (en) 2007-07-25
JP2008519074A (ja) 2008-06-05
AR051755A1 (es) 2007-02-07
WO2006052378A1 (en) 2006-05-18
US7544680B2 (en) 2009-06-09
TW200628470A (en) 2006-08-16
US20080287422A1 (en) 2008-11-20
MX2007005119A (es) 2007-07-04
US20060094707A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
PE20060722A1 (es) Compuestos heterociclicos como antagonistas del receptor cgrp
US10882855B2 (en) Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
DK2718266T3 (en) PYRIDIN-2-AMIDES USED AS CB2 AGONISTS
EP1323710B1 (en) Nitrogenous five-membered ring compounds
AU2007311087B2 (en) Organic compounds
CN1303067C (zh) 用作半光氨酸蛋白酶可逆抑制剂的螺杂环腈
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
CN1072172A (zh) 新颖的7-取代-9-取代氨基-6-去甲基-6-去氧四环素
PE20090815A1 (es) Compuesto de amida
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
AU2003222804A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
PE20110410A1 (es) Derivado de 7-piperidinoalquil-3,4-dihidroquinolona
PE20110793A1 (es) Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona
PE20231746A1 (es) Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos
CN101048383A (zh) 促性腺激素释放激素受体拮抗剂
CN1882529A (zh) 组蛋白脱乙酰基酶抑制剂
PE20091069A1 (es) Derivados de pirazol como inhibidores de 5-lo
PE20070702A1 (es) COMPUESTOS DERIVADOS DE (TRIFLUOROMETOXI-FENIL)-ETILAMINO COMO INHIBIDORES DE LA ACETILCOLINESTERASA Y ANTAGONISTAS DEL RECEPTOR DE ADRENALINA alfa1
PE20061108A1 (es) Derivados de aril 1,4-pirazina sustituidos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed